Bridge Investment Fund

BucketFeet, Inc., based in Chicago, Illinois, is a direct-to-consumer footwear brand that specializes in artist-designed shoes for men, women, and children. Founded in 2011, the company collaborates with a global community of artists to create unique, limited-edition sneakers, with each pair featuring a different artist's design. BucketFeet operates an online platform where customers can order shoes that are printed only after they are purchased, thus reducing unnecessary environmental waste associated with traditional manufacturing cycles. In addition to footwear, the company also offers apparel such as tees, hoodies, and socks. Through its innovative approach, BucketFeet aims to foster meaningful conversations and empower artists to share their stories through the medium of shoes, serving as a canvas for diverse artistic expression. As of late 2017, BucketFeet operates as a subsidiary of SkinnyCorp, LLC.

EarlySense Ltd. specializes in developing advanced patient monitoring systems for healthcare facilities, including hospitals and rehabilitation centers. The company offers a range of products, such as the EarlySense System, which provides continuous monitoring of heart rate, respiratory rate, and patient motion, enabling healthcare teams to detect early signs of patient deterioration and prevent falls and pressure ulcers. Additionally, the Central Display Station allows nurses to supervise multiple patients effectively, while the contact-free consumer health monitor, known as LIVE, provides valuable health information to users and their caregivers. EarlySense's technology is employed in various medical settings, including surgical wards, oncology, and long-term care facilities. Founded in 2004 and headquartered in Ramat Gan, Israel, with a marketing office in Woburn, Massachusetts, the company has formed partnerships to enhance its product offerings and expand its market reach.

EarlySense Ltd. specializes in developing advanced patient monitoring systems for healthcare facilities, including hospitals and rehabilitation centers. The company offers a range of products, such as the EarlySense System, which provides continuous monitoring of heart rate, respiratory rate, and patient motion, enabling healthcare teams to detect early signs of patient deterioration and prevent falls and pressure ulcers. Additionally, the Central Display Station allows nurses to supervise multiple patients effectively, while the contact-free consumer health monitor, known as LIVE, provides valuable health information to users and their caregivers. EarlySense's technology is employed in various medical settings, including surgical wards, oncology, and long-term care facilities. Founded in 2004 and headquartered in Ramat Gan, Israel, with a marketing office in Woburn, Massachusetts, the company has formed partnerships to enhance its product offerings and expand its market reach.

Navotek Medical develops real-time innovative tracking and navigation solutions for medical applications. The first application is in the oncology field, providing tumor localization and tracking for optimal radiation therapy. Navotek’s solution will allow for safer and more effective treatment, improving the chances of tumor eradication and decreasing the rate of complications. In addition, it will potentially improve the efficiency of the treatment procedure by shortening individual sessions as well as entire treatment courses. This will increase the radiation rooms’ throughput which will translate into increased earnings for the hospital.

CritiSense, Ltd. is a medical technology company that specializes in the real-time monitoring of patients' metabolic states, particularly during surgical procedures and in intensive care units. Founded in 2004 and based in Giv'at Shmu'el, Israel, the company has developed the CritiView, a sophisticated monitoring system that provides continuous, real-time data through the assessment of four physiological parameters at the tissue level. This device enables healthcare professionals, including surgeons, anesthesiologists, and ICU caregivers, to identify imbalances in tissue and body vitality by monitoring mitochondrial function, microcirculatory blood flow, and oxygen saturation. The technology, rooted in the expertise of co-founder Professor Avraham Mayevsky, enhances surgical outcomes and patient care by facilitating informed clinical decisions based on comprehensive physiological insights.